

Cereno Scientific – executive interview

In this interview, we speak with Sten Sørensen, CEO of [Cereno Scientific](#), about the company's strong start to 2026 and the key takeaways from the Q126 results. He provides updates on CS1 ahead of its planned Phase IIb trial in pulmonary arterial hypertension (PAH), discusses the advancement of CS014 in PH associated with interstitial lung disease (PH-ILD) and the ongoing pharmacokinetic bridging study, and explains the rationale for selecting antiphospholipid syndrome (APS) as the lead indication for CS585. Sten also highlights how the company's clinical programmes are aligned with the evolving regulatory landscape, helping to de-risk development, and comments on growing interest from potential pharmaceutical partners. He concludes by outlining the key milestones and catalysts investors can expect over the coming months, setting the stage for a newsflow-rich period.

